Navigation Links
Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimer's disease
Date:3/16/2009

PHILADELPHIA, PA A test capable of confirming or ruling out Alzheimer's disease has been validated and standardized by researchers at the University of Pennsylvania School of Medicine. By measuring cerebrospinal fluid (CSF) concentrations of two of the disease's biochemical hallmarks amyloid beta42 peptide and tau protein the test also predicted whether a person's mild cognitive impairment would convert to Alzheimer's disease over time. Researchers were able to detect this devastating disease at the earliest stages, before dementia symptoms appeared and widespread irreversible damage occurred. The findings hold promise in the search for effective pharmaceutical therapies capable of halting the disease.

Honing in on a previously suggested pathological CSF biomarker signature, a team of Penn Medicine researchers, led by Leslie M. Shaw, PhD, Co-Director of the Penn Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core, found evidence of neuron degeneration marked by an increase in CSF concentration of tau proteins and plaque deposition, indicated by a decrease in amyloid beta42 concentration. In addition, people with two copies of the genetic risk factor for Alzheimer's disease, APOE ε4 , had the lowest concentrations of amyloid beta42, compared to those with one or no copies. The study appears in the online edition of the Annals of Neurology.

"With this test, we can reliably detect and track the progression of Alzheimer's disease," said Dr. Shaw. "Validated biomarker tests will improve the focus of Alzheimer's clinical trials, enrolling patients at earlier stages of the disease to find treatments that can at least delay and perhaps stop neurodegeneration. In addition, prevention trials can test methods to delay or block mild cognitive impairment from converting to full-blown Alzheimer's."

Further validation studies of this research test system are underway. Additional work is needed to develop additional biomarkers, as well as identify more genetic risk factors that will help distinguish Alzheimer's from other neurodegenerative diseases characterized by cognitive impairments.

"Thanks to the dedicated researchers and volunteers who participated in this and other Alzheimer's disease studies through the Penn Alzheimer's Disease Core Center and at ADNI trial sites around the US and Canada, we have validated a test where a safe, simple lumbar puncture can provide information to confirm suspected Alzheimer's disease and predict the onset of the disease," said John Q. Trojanowski, MD, PhD, Director of the Penn Alzheimer's Disease Core Center. "Using this technique, we will further our understanding of how the disease progresses and what we can do to stop Alzheimer's disease before it starts."

About the Study

Cerebral spinal fluid samples contributed by 410 ADNI volunteers at 56 sites across the U.S. and Canada were included in this study. To independently establish threshold values for these biomarkers, cerebrospinal fluid samples from 52 Penn Memory Center volunteers with normal cognition and 56 people with confirmed Alzheimer's disease based on post-mortem autopsy diagnosis were also measured. The test was based on the multiplexed xMAP microbead immunoassay system, with reagents provided by Innogenetics.

When compared with normal, healthy adults of the same age, a pattern of changes emerged in people with mild cognitive impairment or Alzheimer's disease. In this group, tau concentrations increased, while amyloid beta42 levels decreased as the disease progressed.

  • The test was 87 percent accurate overall (80 percent or above is considered clinically useful).
  • In the CSF samples from those with autopsy-confirmed Alzheimer's disease, the amyloid beta42 concentration threshold was most sensitive and detected Alzheimer's disease at a rate of 96.4 percent.
  • The test accurately ruled out Alzheimer's disease in 95.2 percent of the subjects.
  • The test positively predicted the conversion from mild cognitive impairment to Alzheimer's disease at a rate of 81.8 percent.

Data used in preparing this article were produced by the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core at Penn or obtained from the ADNI database (www.loni.ucla.edu/ADNI). Many ADNI investigators contributed to the design and implementation of ADNI or provided information but did not participate in the analysis of the data presented here or in the writing of this report. A complete list of ANDI investigators is available at http://www.loni.ucla.edu/ADNI/Collaboration/ADNI_Authorship_list.pdf.


'/>"/>

Contact: Kim Guenther
kim.guenther@uphs.upenn.edu
215-200-2312
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Media Advisory: Medco CEO David B. Snow Jr. To Address American Enterprise Institute: Health IT: Empowering Precision Medicine
2. Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
3. ACP Medicine Names New Editor, Looks Toward Future of Medicine
4. Englewood Hospital Marks 15 Years of Leadership in Improving Patient Outcomes Through Bloodless Medicine and Surgery
5. CompuCyte Corporation and Program in Cellular and Molecular Medicine at Childrens Hospital Boston Announce Joint Program for Quantitative Imaging Cytometry Research Services
6. New Research Released at Annual Society for Adolescent Medicine Meeting Provides Vital Insights into Adolescent Health Issues
7. The American Heart Association and Macys Join Forces to Drive Diversity in Medicine
8. Frost & Sullivan: Ageing Population and Availability of Preventative Medicines Propels Growth of European Eye Health Ingredients Market
9. BioFortis Wins Best Product Award in Discovery Informatics at the 2009 Molecular Medicine Tri-Conference
10. MedicinePhone Launches TouchOut Cancer on Apple App Store
11. Best New Product Awards Winners Named at Molecular Medicine Tri-Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... , ... US Sport Camps is pleased to announce the addition of junior ... as the host site and directing the camps is PGA Professional and 2008 Iowa ... in recent years around Des Moines and are fortunate to have such a well-respected ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... A lot ... past 35 years. A president has access to health and wellness resources most Americans ... free world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Healthcare careers in the medical laboratory, nursing, ... via the website of healthcare staffing leader Aureus Medical Group during the month of ... travel therapy positions and in travel and direct hire opportunities in other ...
(Date:2/12/2016)... ... , ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual ... for teens with and without special needs to gather in a safe and supportive environment. ... dance will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... in the field of long term care. With that, says Patrick Loughney, president ... professionals in administrative roles in long term care environments. His company, which offers ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
Breaking Medicine Technology: